Leishmania donovani cannot synthesize purines de novo and obligatorily scavenge purines from the host. Previously, we described a conditional lethal ⌬hgprt/⌬xprt mutant of L. donovani (Boitz, J. M., and Ullman, B. (2006) J. Biol. Chem. 281, 16084 -16089) that establishes that L. donovani salvages purines primarily through hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT). Unlike wild type L. donovani, the ⌬hgprt/⌬xprt knockout cannot grow on 6-oxypurines and displays an absolute requirement for adenine or adenosine and 2-deoxycoformycin, an inhibitor of parasite adenine aminohydrolase activity. Here, we demonstrate that the ability of ⌬hgprt/⌬xprt parasites to infect mice was profoundly compromised. Surprisingly, mutant parasites that survived the initial passage through mice partially regained their virulence properties, exhibiting a >10-fold increase in parasite burden in a subsequent mouse infection. To dissect the mechanism by which ⌬hgprt/⌬xprt parasites persisted in vivo, suppressor strains that had regained their capacity to grow under restrictive conditions were cloned from cultured ⌬hgprt/⌬xprt parasites. The ability of these suppressor clones to grow in and metabolize 6-oxypurines could be ascribed to a marked amplification and overexpression of the adenine phosphoribosyltransferase (APRT) gene. Moreover, transfection of ⌬hgprt/⌬xprt cells with an APRT episome recapitulated the suppressor phenotype in vitro and enabled growth on 6-oxypurines. Biochemical studies further showed that hypoxanthine, unexpectedly, was an inefficient substrate for APRT, evidence that could account for the ability of the suppressors to metabolize hypoxanthine. Subsequent analysis implied that APRT amplification was also a potential contributory mechanism by which ⌬hgprt/⌬xprt parasites displayed persistence and increased virulence in mice.Leishmania donovani is a protozoan parasite that is the causative agent of visceral leishmaniasis, a debilitating and often fatal disease in humans. Leishmania spp. are digenetic protozoan parasites that exist as flagellated, motile promastigotes within the alimentary tract and salivary glands of their insect vector, members of the Phlebotomine sandfly family and as nonflagellated, amotile amastigotes within macrophages and other reticuloendothelial cells of the mammalian host. No effective vaccines are available for visceral leishmaniasis-or for that matter any disease caused by protozoan parasites, and therefore chemotherapy offers the only means of defense for the treatment and prevention of leishmaniasis and other diseases of parasitic origin. Unfortunately, the current armamentarium of drugs employed against visceral and other forms of leishmaniasis is far from ideal and is adversely affected by toxicity, protracted and invasive routes of administration, and therapeutic unresponsiveness. As a result, there is an acute need for better and more efficacious drugs to combat the disease.The establishment of an efficacious, parasite-specific ...